onc Videos

Videos

Mostafa Eyada, MD, University of Texas, Medical Branch

Videos

Bevacizumab Plus Oral Cyclophosphamide Demonstrated Safety, Efficacy Among Patients With Recurrent Platinum-Resistant Ovarian Cancer

06/19/2024

Mostafa Eyada, MD

Mostafa Eyada, MD, describes a retrospective analysis assessing the safety and efficacy of bevacizumab plus oral cyclophosphamide among patients with recurrent high-grade platinum-resistant ovarian, fallopian tube, and primary peritoneal...

Mostafa Eyada, MD, describes a...

06/19/2024

Oncology

Conference Coverage

Adagrasib Improved Survival and Response Among Patients With KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

06/17/2024

Tony Mok, MD

According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.

According to results from the...

06/17/2024

Oncology

Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD

Roundtables

Managing Patients With HER2-Positive Metastatic Breast Cancer

06/17/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.

In this video, a panel of...

06/17/2024

Oncology

Roundtables

Sequencing Antibody Drug Conjugates for Patients With HER2-Low Metastatic Breast Cancer

06/17/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the sequencing of antibody drug conjugates of patients with HER2-low metastatic breast cancer, including trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan.

In this video, a panel of...

06/17/2024

Oncology

Roundtables

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

06/14/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the management of patients with HER2-low metastatic breast cancer, sharing data from the DESTINY-Breast06 trial.

In this video, a panel of...

06/14/2024

Oncology

Conference Coverage

Examining Efficacy and Safety of Novel Armored huCART19-IL18 Treatment for Patients With R/R Lymphoma

06/13/2024

Featuring Jakub Svoboda, MD

Jakub Svoboda, MD, discusses preliminary research that examines the safety and efficacy of armored huCART19-IL18 among patients with relapsed/refractory non-Hodgkin lymphoma that progressed after anti-CD19 CAR T-cells.

Jakub Svoboda, MD, discusses...

06/13/2024

Oncology

Frederik Marmé, PhD, Heidelberg University

Videos

Atezolizumab Plus Chemotherapy and Bevacizumab Did Not Improve Survival For Patients With Recurrent Platinum-Resistant Ovarian Cancer

06/13/2024

Frederik Marmé, MD, PhD

According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...

According to phase 3 data, the...

06/13/2024

Oncology

Kevin Kalinsky, MD, Winship Cancer Institute

Videos

Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

06/13/2024

Kevin Kalinsky, MD

Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...

Kevin Kalinsky, MD, shares...

06/13/2024

Oncology

Conference Coverage

Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL

06/11/2024

Featuring Matthew Matasar, MD

Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...

Matthew Matasar, MD, discusses...

06/11/2024

Oncology

Videos

Evaluating Epcoritamab Plus Rituximab and Lenalidomide for Frontline Treatment and Epcoritamab as Maintenance Therapy for Patients With FL

06/08/2024

Featuring Joshua Brody, MD

According to data presented at the 2024 ASCO Annual Meeting, epcoritamab plus rituximab and lenalidomide continued to demonstrate deep, durable responses for previously untreated FL, and epcoritamab as maintenance therapy showed efficacy and...

According to data presented at...

06/08/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology